On Friday, ENSCO PLC (NYSE:ESV)’s shares declined -1.50% to $23.66, after ENSCO PLC (ESV), will hold its first quarter 2015 earnings conference call at 10:00 a.m. CDT (11:00 a.m. EDT and 4:00 p.m. London) on Thursday, 30 April 2015. The earnings release will be issued before the New York Stock Exchange opens that morning.
Ensco plc provides offshore contract drilling services to the oil and gas industry worldwide. The corporation operates through three segments: Floaters, Jackups, and Other. The corporation owns and operates offshore drilling rig fleet of 70 rigs, counting 10 drillships, 13 semisubmersible rigs, 5 moored semisubmersible rigs, and 42 jackup rigs located in North and South America, the Middle East and Africa, the Asia Pacific rim, Europe and the Mediterranean, and Brazil.
Integrated Device Technology Inc (NASDAQ:IDTI)’s shares dropped -1.44% to $20.26, during the last trading session on Friday, as Integrated Device Technology Inc (IDTI ), declared that Robert A. Rango, a former Broadcom Corp. executive with extensive leadership skills in the global semiconductor market, has been designated to IDT’s Board of Directors, effective April 6, 2015.
“Bob brings noteworthy operating and leadership skills and has successfully run businesses in the mobile, wireless and network infrastructure segment,” said IDT Board Chairman John Schofield. “His executive experience in the global semiconductor industry is invaluable, and we are looking forward to Bob’s contributions as a member of our Board.”
“As anyone following IDT closely knows, this is an exciting time to join the corporation,” Rango said. “I look forward to working with my fellow board members in supporting IDT’s executive team as it works hard to deliver strong financial results and leading technology to its investors and customers.”
Integrated Device Technology, Inc. designs, develops, manufactures, and markets a range of mixed signal semiconductor solutions for the communications, computing, and consumer industries worldwide. It operates in two segments, Communications, and Computing and Consumer.
At the end of Friday’s trade, Cobalt International Energy, Inc (NYSE:CIE)‘s shares dipped -1.46% to $10.13, as Cobalt International Energy, Inc (CIE), declared that it has plugged and abandoned its North Platte #2 appraisal well in the deepwater Gulf of Mexico due to a seal failure in the riser connection system. The well, which was being drilled with the Rowan Reliance drillship, was at a depth of 20,701 feet when the problem with the riser was detected. The well was permanently abandoned proceeding to reaching any geological targets.
Cobalt is presently permitting the North Platte #3 well about 200 feet from the surface location of the North Platte #2 well. Assuming timely receipt of permit approval, Cobalt anticipates spudding the North Platte #3 well within two weeks and continues to expect well results in the second half of 2015.
Cobalt International Energy, Inc., through its auxiliaries, engages in the exploration and production of oil-focused, below-salt exploration prospects. Its project portfolio comprises North Platte, Heidelberg, Shenandoah, and Anchor discovery in the U.S. Gulf of Mexico; Cameia, Lontra, Mavinga, Bicuar, and Orca in the offshore Angola; and Diaman in the offshore Gabon. As of December 31, 2014, the corporation’s estimated net proved undeveloped reserves totaled 8.4 million barrels of oil and 3.7 billion cubic feet of natural gas.
Galena Biopharma Inc (NASDAQ:GALE), ended its Friday’s trading session with -1.43% loss, and closed at $1.38, hitting its lowest level, after Galena Biopharma Inc (GALE), declared the closing of the exercise of the underwriters’ option to purchase an additional 3,653,846 shares of ordinary stock of Galena at a price of $1.457 per share as part of the firm commitment underwritten offering that closed initially on March 18, 2015.
The additional net proceeds to Galena from the exercise of the option with respect to the shares are about $5.4 million, bringing the total net proceeds to Galena from the offering to about $40.8 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by Galena.
Raymond James & Associates, Inc. acted as the sole book-running manager for the offering. Roth Capital Partners acted as lead manager, and Maxim Group LLC, Noble Life Science Partners, and MLV & Co. LLC acted as co-managers.
Galena Biopharma, Inc., a biopharmaceutical corporation, focuses on developing and commercializing oncology therapeutics that address major unmet medical needs across cancer care. Its commercial products comprise Abstral, a sublingual tablet that is used for the administration of breakthrough pain in patients with cancer; and Zuplenz, an oral soluble film for use in the prevention of emetogenic chemotherapy-induced, radiotherapy-induced, and post-operative nausea and vomiting.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
